Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Electrical Status Epilepticus of Sleep (ESES)
NCT04721691Phase 1Completed
- Sponsor
- Northwell Health
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in Electrical status epilepticus in sleep (ESES) (2 arms), sponsored by Northwell Health. Primary endpoint: Frequency of Spike Wave Index up to 20 weeks. Started Mar 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
Electrical status epilepticus in sleep (ESES)
Beyond the preview
Go deeper on NCT04721691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721691.